Navigation Links
Optimer Pharmaceuticals Reports Second Quarter 2012 Financial Results

SAN DIEGO, July 31, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced the Company's financial results for the quarter ended June 30, 2012.


Second Quarter 2012 Financial Highlights:

  • DIFICID® second quarter gross sales of $18.0 million and net sales of $15.2 million, represent increases of 9% and 6% over the first quarter, respectively
  • DIFICID ex-wholesaler treatments shipped in the second quarter to hospitals, retail pharmacies and long-term care facilities increased by 11%
  • Surpassed the first-year net sales goal established with Cubist, triggering a $5 million milestone payment due to Cubist
  • Total revenues were $49.8 million, including $19.9 million for partnering with Astellas in Japan and a $12.6 million milestone from Astellas Pharma Europe for the launch of DIFICLIR™ in the EU
  • Cash, cash equivalents and short-term investments at June 30 totaled $130.6 million
  • Net loss for the second quarter was $296,000, or $0.01 per share

    "July marked the one-year anniversary of the launch of DIFICID, and we are very proud of our accomplishments. We've generated $51.1 million in net sales and shipped almost 21,000 treatments of DIFICID since launch through the end of June this year," stated Pedro Lichtinger, President and Chief Executive Officer of Optimer. "Both demand for, and access to, DIFICID continue to grow, as scientific and health economic understanding is being expanded through more than 90 publications to date. We are confident in DIFICID's potential to meet our expectations in 2012 and also maintain expectations for reaching break-even within 3 years of launch."

    Financial Overview
    Total revenues for the thr

    SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
    2. Global Biopharmaceuticals Market 2011-2015
    3. Patient Advocate Foundation and Jazz Pharmaceuticals Announce Partnership for Narcolepsy CareLine
    4. Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
    5. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
    6. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
    7. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
    8. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
    9. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
    10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
    11. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    Post Your Comments:
    (Date:7/24/2014)... 2014  Now available is a stem cell therapy ... Therapies , located in Guadalajara, Mexico ... a new health option: stem cell therapies for ... patients suffer from joint and muscle injuries due to ... torn rotator cuff, tennis elbow, and knee injuries. Throughout ...
    (Date:7/24/2014)... Calif. , July 24, 2014  Asterias ... in the emerging field of regenerative medicine, announced ... of a presentation to investors on Tuesday, July ... PDT.  The presentation will include an overview of ... access the webcast, visit at ...
    (Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
    (Date:7/24/2014)... forces worldwide rely on sophisticated equipment, trained personnel, ... public areas against terrorist attacks. A revolutionary new ... to make their job much easier. , The ... of Tel Aviv University ,s School of Chemistry ... by the Herzliya company Tracense, picks up the ...
    Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
    ... Immunologics announces the filing of two important provisional ... Inc. (QI), a Florida-based company specializing in cancer ... relating to their work in cancer immunotherapy. The ... the oncofetal antigen ("OFA"), or more specifically, iLRP ...
    ... March 31 ArunA Biomedical, Inc., a leader in ... it has been awarded a Department of Defense contract ... cell technology. (Logo: ... embryonic stem cell derived cellular model for use in ...
    ... 31 , - Books Authored ... Two of the biggest names in health care ... exclusive agreement to,co-publish International Classification of Diseases, Ninth Revision, Clinical,Modification ... J. Buck, beginning with the 2010 editions, in fall 2009. ...
    Cached Biology Technology:Immunotherapy-Based Provisional Patents Mark Significant Discovery 2Immunotherapy-Based Provisional Patents Mark Significant Discovery 3ArunA Biomedical Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security 2The American Medical Association and Elsevier Join to Co-Publish ICD-9-CM and HCPCS Coding Reference Books 2The American Medical Association and Elsevier Join to Co-Publish ICD-9-CM and HCPCS Coding Reference Books 3
    (Date:7/24/2014)... /PRNewswire-iReach/ -- The Geneva Healthcare Suite, an innovative technology ... emergency room wait times by an average of 92 ... according to a recent study published in the Academic ... the suite to access data from incoming patients, implanted ... "Using Geneva,s technology platform we have been able to ...
    (Date:7/24/2014)... NEW YORK, NY (July 24, 2014) Scientists ... Research Institute are one step closer to creating ... from a patient,s own cells. , For ... stem (iPS) cells lines from skin samples of ... they developed an accelerated protocol to induce these ...
    (Date:7/24/2014)... of native animal species for food or commercial food ... factor in the decline of many species of primates ... that more than half of the species being consumed ... "By surveying not only the meat made available for ... the forest by hunters and brought to villages for ...
    Breaking Biology News(10 mins):UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 2UC San Diego Medical Center Cuts Average ER Wait Time by 92 Minutes using the Geneva Healthcare Suite 3NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2
    ... Texas AgriLife Research scientists finds that contrary to widespread perceptions, ... stream flows, have not been declining as a result of ... twice as high as they were prior to 1950. ... intensive livestock grazing in Texas that dates back to the ...
    ... University,s Department of Biology has recently returned from a meeting ... The Crocusbank project centres round saffron as a spice ... Its aim is to improve saffron production, a crop which ... and is both sustainable and of very high value. The ...
    ... , , , , , ... , AUDIO: Dr. Theresa ... Click here for more information. , , ... , , , , , ...
    Cached Biology News:Study shows woody plant encroachment has increased stream flow in the Edwards Plateau 2Leicester's internationally acclaimed genetics research involved in project into saffron production 2New study shows teens who drink 100 percent fruit juice have more nutritious diets overall 2New study shows teens who drink 100 percent fruit juice have more nutritious diets overall 3
    ... 100 ml supplied as a 5x ... antibodies from membrane-bound proteins without destroying ... chemiluminescent or radioisotopic signals from blots. ... blots. Supplied as a 5X solution ...
    ... This marker is specifically designed for ... IEF. The four proteins in this ... a diagonal pattern across a 2D ... to 3.8. Mol ...
    High-throughput DNA preparation and end sequencing of BAC libraries. 3730xl DNA sequencers. LIMS tracking utilizing Geospiza's Finch system. Full-length BAC sequencing also available. Our expertise h...
    Biology Products: